Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

An implant includes a membrane having pores sized in the nanometer range. A surface of the implant is at least partially coated with a plasma polymer. The interior of the pores is uncoated.

Pyruvate may be used to stabilize hyaluronic acid compositions. For example, these compositions may have improved heat and/or storage stability.

One aspect of the invention provides a method of preventing or reducing stenosis in a subject. The method includes implanting a passivated graft comprising vein into an artery. The implanting of the graft replaces and/or bypasses a diseased segment of the artery. The passivated graft including vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (TSSA) under conditions sufficient to promote cross-linking of proteins within the vein.

A method of making infused bone fibers employs the following steps: cutting or shaving whole bone into bone fibers, washing the bone fibers, demineralizing or decalcifying at least partially the whole bone or bone fibers and infusing the bone fibers with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused bone fibers. The step of infusing includes exposing the bone fibers to a negative pressure or vacuum to draw the supernatant and/or the polyampholyte cryoprotectant into the bone fibers, or alternatively, exposing the demineralized whole bone to a positive pressure to drive the supernatant and/or the polyampholyte cryoprotectant into the bone. The resultant method creates an infused bone grafting composition having bone fibers taken from whole bone, demineralized or decalcified at least partially and infused with one or more of a supernatant of biologic material or a polyampholyte cryoprotectant or both.

The present invention disclosed a process to coat the surface of flexible polymeric implant with biocompatible polymer such that the coating does not crack when the implant is subjected to mechanical forces such as tension, torsion or bending while retaining the inherent properties of the coated polymer.

The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.

Pyruvate may be used to stabilize hyaluronic acid compositions. For example, these compositions may have improved heat and/or storage stability.

The invention relates to the use of inhibiting calcium carbonate as an additive for a composition used in an implant, the composition containing at least one polymer different from cellulose, and the inhibiting calcium carbonate being obtainable by a method in which calcium carbonate particles are coated with a composition that contains, each relative to its total weight, a mixture of at least 0.1 wt.-% of at least one calcium complexing agent and/or at least one conjugated base which is an alkali metal salt or calcium salt of a weak acid, together with at least 0.1 wt.-% of at least one weak acid.

The invention further relates to an implant comprising a composition that contains at least one polymer different from cellulose and inhibiting calcium carbonate, said inhibiting calcium carbonate being obtainable by a method in which calcium carbonate particles are coated with a composition that contains, each relative to its total weight, a mixture of at least 0.1 wt.-% of at least one calcium complexing agent and/or at least one conjugated base which is an alkali metal salt or calcium salt of a weak acid, together with at least 0.1 wt.-% of at least one weak acid.

The three-dimensional lattice structures disclosed herein have applications including use in medical implants. Some examples of the lattice structure are structural in that they can be used to provide structural support or mechanical spacing. In some examples, the lattice can be configured as a scaffold to support bone or tissue growth. Some examples can use a repeating modified rhombic dodecahedron or radial dodeca-rhombus unit cell. The lattice structures are also capable of providing a lattice structure with anisotropic properties to better suit the lattice for its intended purpose.